开发ARL4C反感性寡核酸,减少非目标效应,提高作为抗癌药物的有效性
Kanae Kawai1, Shinji Matsumoto2,3, Akikazu Harada2,4
1Department of Physiology, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
In vitro cellular & developmental biology. Animal
|March 6, 2026
概括
一种新的反感性寡核酸 (ASO),ASO-2025-A/L,有效地向癌细胞中的ARL4C,抑制瘤生长,与以前的疗法相比,具有较少的脱效应. 这种改进的ARL4C ASO疗法显示了增强癌症治疗的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- ARL4C是一种小的GTP结合蛋白,在各种癌症类型中经常过度表达.
- 反感性寡核酸 (ASO) 疗法,如15-mer ASO-1316-A,通过向ARL4C.显示出抑制瘤生长的潜力.
- 提高治疗效率和最大限度地减少目标外影响对于开发有效的ASO治疗至关重要.
研究的目的:
- 与ASO-1316-A相比,开发和评估新的18-merARL4C向ASO,其有效性提高,目标外影响减少.
- 评估领先候选ASO,ASO-2025-A/L在相关癌症模型中的体外和体内性能.
- 调查ASO-2025-A/L对ARL4C表达,癌细胞行为和潜在的目标外基因调节的影响.
主要方法:
- 开发了14个18年来针对ARL4C的ASO.
- 在体外评估ASO对癌细胞增殖,迁移和粘附 (PANC-1,S2-CP8,PC-9细胞) 的疗效.
- RNA测序分析以确认基因表达变化和识别非目标效应.
- 在异种移植瘤模型 (PC-9和PANC-1细胞) 中对ASO-2025-A/L的体内评估和肝毒性标志物的评估.
主要成果:
- 与ASO-1316-A.A.相比,ASO-2025-A/L表现出更好的ARL4CmRNA和蛋白质的抑制.
- 在体外,ASO-2025-A/L显著抑制了胰腺和肺癌细胞的增殖,迁移和粘附.
- ASO-2025-A/L显示了预测的目标基因 (26 vs. 2824) 的显著减少,并证实了细胞粘附途径基因的下调.
- 在体内,ASO-2025-A/L有效地抑制了异种移植瘤的生长,而不会诱导肝脏毒性.
结论:
- ASO-2025-A/L代表了一种改进的18-mer ARL4C向ASO,具有增强的治疗潜力.
- 这种新型的ASO在抑制癌细胞功能和瘤生长方面表现出卓越的疗效.
- ASO-2025-A/L提供了一个有前途的治疗策略,显著降低了非目标效应的特征.
相关概念视频
Experimental RNAi
8.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.1K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
siRNA - Small Interfering RNAs
18.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.9K
RNA Interference
28.4K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.4K


